- Home
- ONMD vs GDTC Comparison
ONMD vs GDTC Comparison
Compare ONMD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- GDTC
- Stock Information
- Founded
- ONMD 2006
- GDTC 2018
- Country
- ONMD United States
- GDTC Singapore
- Employees
- ONMD N/A
- GDTC 34
- Industry
- ONMD
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- ONMD
- GDTC Health Care
- Exchange
- ONMD Nasdaq
- GDTC Nasdaq
- Market Cap
- ONMD 23.9M
- GDTC 25.7M
- IPO Year
- ONMD N/A
- GDTC 2023
- Fundamental
- Price
- ONMD $0.84
- GDTC $2.20
- Analyst Decision
- ONMD
- GDTC Buy
- Analyst Count
- ONMD 0
- GDTC 1
- Target Price
- ONMD N/A
- GDTC $5.00
- AVG Volume (30 Days)
- ONMD 498.5K
- GDTC 13.3K
- Earning Date
- ONMD 12-03-2024
- GDTC 01-01-0001
- Dividend Yield
- ONMD N/A
- GDTC N/A
- EPS Growth
- ONMD N/A
- GDTC N/A
- EPS
- ONMD N/A
- GDTC N/A
- Revenue
- ONMD $1,021,651.00
- GDTC $330,254.00
- Revenue This Year
- ONMD N/A
- GDTC $14.71
- Revenue Next Year
- ONMD N/A
- GDTC N/A
- P/E Ratio
- ONMD N/A
- GDTC N/A
- Revenue Growth
- ONMD N/A
- GDTC N/A
- 52 Week Low
- ONMD $0.42
- GDTC $1.20
- 52 Week High
- ONMD $4.43
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- ONMD 52.31
- GDTC 49.23
- Support Level
- ONMD $0.81
- GDTC $1.88
- Resistance Level
- ONMD $0.87
- GDTC $2.35
- Average True Range (ATR)
- ONMD 0.13
- GDTC 0.36
- MACD
- ONMD -0.00
- GDTC -0.05
- Stochastic Oscillator
- ONMD 53.27
- GDTC 37.00
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.